

## Sensorion to Present New SENS-401 Data at ARO 2019 MidWinter Meeting, Feb. 9-13, 2019

*Two poster presentations to show growing evidence base for SENS-401 in inner ear disease*

**Montpellier, February 13, 2019 – Sensorion (FR0012596468 – ALSEN / PEA-PME eligible)**, a biotech company specializing in the treatment of inner ear diseases, today announced new data presented on three posters at the Association for Research in Otolaryngology's (ARO) 42nd Annual MidWinter Meeting in Baltimore, Maryland.

- “Lasting **SENS-401 Protection of Cochlear Hair Cells** in Organ of Corti Explant Cultures following Gentamicin Ototoxic Insult In Vitro

These preliminary results are consistent with a mechanism of action able to reduce hair cell death through both the extrinsic and intrinsic apoptotic pathways. Further experiments will determine the extent of functional otoprotection against aminoglycoside ototoxicity by oral administration of SENS-401 *in vivo*.

- **Comparison of SENS-401** Inner Ear Tissue and Perilymph Exposure after Oral Administration in Rat, Guinea Pig and Cat

Although these data demonstrate some species differences, high nanomolar SENS-401 concentrations were achieved in both perilymph and inner ear tissue after oral administration in all three species. This demonstrates that local target exposure is not specific to a single species and thus otoprotectant efficacy may also be generalized.

- **Wireless Inertial Measurement** of Activity and Head Kinematics in a Rat Model of Acute Unilateral Vestibular Loss Reveal Persistent Dynamic Vestibular Deficit Symptoms

Contrary to other approaches, in quantitative posture-locomotor evaluation such as video monitoring, the inertial sensor output is immediately quantitative, does not require large amounts of digital storage space and is easily treatable using mathematical transformations in broadly available software packages such as MatLab or R.

The described persistent changes in spontaneous activity level and head kinematics demonstrate the ability of wireless inertial measurements in freely moving animal models to deliver translationally valid, clinically relevant outcome measures for evaluation of long-term effects of acute phase vertigo interventions as well as pharmaceutical strategies for enhancing central compensation.

### About SENS-401

SENS-401, Arazasetron, is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequela hearing impairments. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the ~~Press-release~~ treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population.

### About Sensorion

Sensorion is a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, vertigo and tinnitus. Our clinical-stage portfolio includes two phase 2 products: Seliforant (SENS-111) under investigation for acute unilateral vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural hearing loss (SSNHL). We have built a unique R&D technology platform to expand our understanding of the pathophysiology and etiology of inner ear related diseases enabling us to select the best targets and modalities for drug candidates. We also identify biomarkers to improve diagnosis and treatment of these underserved illnesses.

**Press release**

In its drive to continue to deliver additional groundbreaking therapeutic solutions for inner ear patients, Sensorion entered into exclusive negotiations, in November 2018, with Pasteur Institute for hearing loss gene therapy programs including among others the Usher Syndrome Type1 and Otoferlin-deficiency.

We are uniquely placed through our platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet need in medicine today.

[www.sensorion-pharma.com](http://www.sensorion-pharma.com)

**Contacts**

**Sensorion**

Nawal Ouzren  
CEO

[contact@sensorion-pharma.com](mailto:contact@sensorion-pharma.com)

Tél : +334 67 20 77 30

**Investor Relations**

**LifeSci Advisors LLC**

Hans Herklots – Managing Director

[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

Tél. : +41 79 598 7149

Label : **SENSORION**

ISIN : **FR0012596468**

Mnemonic : **ALSEN**



**Disclaimer**

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF-French Financial Market Authority) on September 6, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.